Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
KNOW LABS, INC. (KNWN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
09/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2023 8-K Quarterly results, Conference call transcript
Docs: "Know Labs, Inc. Reports Third Quarter FY2023 Results SEATTLE – August 14, 2023 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights :",
"Transcript of Earnings Conference Call",
"Presentation"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "Restatement of the Articles of Incorporation",
"KNOW LABS, INC. SECOND AMENDED AND RESTATED BYLAWS",
"Amended and Restated Series C Certificate of Designation",
"Third Amended and Restated Series C Certificate of Designation",
"Series D Certificate of Correction of Know Labs, Inc.",
"Amended and Restated Series D Certificate of Designation",
"Certificate of Withdrawal of Series F Preferred Stock"
08/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/26/2023 8-K Quarterly results
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SEATTLE – June 7, 2023 – Know Labs , an emerging developer of non-invasive medical diagnostic technology, revealed the next stage in the development of its proprietary Bio-RFID™ technology – the Generation 1 Device. Gen 1 incorporates Know Labs’ Bio-RFID sensor – which has been proven as technically feasible and stable in delivering repeatable results in measuring blood glucose when used in a lab environment – in a portable device. Currently, there are no medical-grade, commercially available, non-invasive means of measuring blood glucose. The completion of Gen 1 brings Know Labs closer to achieving its ultimate goal of delivering the world’s first FDA-cleared non-invasive blood glucose monitor for the billions of people living with diabetes and pre-diabetes worldwide. The Gen 1 prot..."
05/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring"
04/21/2023 8-K Quarterly results
03/22/2023 8-K Quarterly results
02/22/2023 SC 13G Bosua Phillip reports a 6.2% stake in KNOW LABS, INC.
02/14/2023 10-Q Quarterly Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Baszucki Todd reports a 9.5% stake in KNOW LABS, INC.
02/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "STRATEGIC PARTNERS NEWS RELEASE"
01/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Know Labs Announces Executive Leadership Changes and Confirms 2023 Outlook SEATTLE – Jan. 27, 2023 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today announced changes to its executive leadership team. The new structure will help the Company accelerate the development and delivery of its non-invasive medical diagnostics technology, Bio-RFID TM , and better position Know Labs for long-term growth and shareholder value creation. As announced, Ron Erickson, Founder and Chairman at Know Labs, was unanimously named Chief Executive Officer by the Company’s Board of Directors. Erickson has been with the Company and its predecessors for nearly 20 years. He brings 30 years of board, business development, financial and executive leadership experience acros..."
01/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/25/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 9 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith",
"Amendment 9 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith"
01/23/2023 8-K Quarterly results
01/04/2023 8-K Quarterly results
12/21/2022 AW Form AW - Amendment Withdrawal Request:
12/20/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
12/20/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/20/2022 AW Form AW - Amendment Withdrawal Request:
12/20/2022 10-K Annual Report for the period ended September 30, 2022
12/19/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
12/14/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/09/2022 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 7 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Extension of Warrant Agreement by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith"
12/09/2022 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 8 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith",
"Amendment 8 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith"
12/09/2022 D Form D - Notice of Exempt Offering of Securities:
12/08/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
12/02/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/16/2022 8-K Investor presentation
Docs: "Know Labs Presentation, 2nd Annual Bernstein CGM Disruptors Conference"
09/21/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Know Labs, Inc. and Boustead Securities, LLC",
"Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 20, 2022",
"Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock SEATTLE – Sept. 20, 2022 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Know Labs, was $8.28 million. The Common Stock began trading on the NYSE American under the symbol “KNW” on September 16, 2022. Boustead Securities, LLC acted as the sole underwriter, on a firm commitment bas..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy